IVF vs HOLX vs NTRA vs INMD vs EXAS

For growth investors, INVO Fertility, Inc.

(IVF) is the stronger pick with 116. 3% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, InMode Ltd.

(INMD) is the cheapest at 9. 8x versus Hologic, Inc. at 30. 5x. On forward P/E, InMode Ltd. is actually cheaper at 10. 3x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +114. 4%, compared to -100. 0% for INVO Fertility, Inc. (IVF). Over 10 years, the gap is even starker: NTRA returned +1835% versus IVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus INVO Fertility, Inc. 's 1. 29β — meaning IVF is approximately 2347% more volatile than EXAS relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INVO Fertility, Inc.

(IVF) is pulling ahead at 116. 3% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -139. 3% for INVO Fertility, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -124. 4% for IVF. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InMode Ltd.

(INMD) trades at 10. 3x forward P/E versus 582. 8x for Exact Sciences Corporation — 572. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTRA: 36. 8% to $265. 63.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, IVF: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IVF is a small-cap high-growth stock; HOLX is a mid-cap quality compounder stock; NTRA is a mid-cap high-growth stock; INMD is a small-cap deep-value stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.